- CGRP receptor antagonists, offering targeted therapeutic relief for migraine by blocking the activity of calcitonin gene-related peptide, are becoming essential in modern neurology due to their efficacy, favorable safety profiles, and suitability for both acute and preventive treatment strategies
- The escalating demand for CGRP receptor antagonists is primarily fueled by the global rise in migraine prevalence, increasing patient awareness, and the limitations of traditional therapies that often lead to poor compliance or adverse effects
- North America dominated the calcitonin gene-related peptide receptor antagonist market with the largest revenue share of 42.2% in 2024, supported by robust healthcare infrastructure, high diagnosis and treatment rates, and early adoption of novel therapeutics, particularly in the U.S. where major pharmaceutical players continue to innovate and expand CGRP-based treatment offerings
- Asia-Pacific is expected to be the fastest growing region in the calcitonin gene-related peptide receptor antagonist market during the forecast period due to improving healthcare access, growing public health awareness, and rising investments in neurology-focused research and clinical trials
- The oral segment dominated the calcitonin gene-related peptide receptor antagonist market with a market share of 45.8% in 2024, driven by patient preference for ease of administration and the availability of multiple FDA-approved oral CGRP treatments for acute migraine therapy
